IBAB logo

Ion Beam Applications SA Stock Price

ENXTBR:IBAB Community·€324.9m Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 13 Fair Values set on narratives written by author

IBAB Share Price Performance

€11.10
-2.48 (-18.26%)
33.4% undervalued intrinsic discount
€16.67
Fair Value
€11.10
-2.48 (-18.26%)
33.4% undervalued intrinsic discount
€16.67
Fair Value
Price €11.10
AnalystConsensusTarget €16.67

IBAB Community Narratives

AnalystConsensusTarget·
Fair Value €16.67 33.4% undervalued intrinsic discount

Proton Therapy Expansion Will Transform Global Cancer Treatment

0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative

Recent IBAB News & Updates

Additional Considerations Required While Assessing Ion Beam Applications' (EBR:IBAB) Strong Earnings

May 05
Additional Considerations Required While Assessing Ion Beam Applications' (EBR:IBAB) Strong Earnings
User avatar

Actinium-225 Production Expansion Will Capitalize On Next-Generation Cancer Treatments

Proton Therapy installations and clinical evidence driving competitive advantage, with expected growth in service revenues and improved market access, enhancing net and gross margins.

Ion Beam Applications SA Key Details

€585.8m

Revenue

€400.7m

Cost of Revenue

€185.1m

Gross Profit

€168.1m

Other Expenses

€17.0m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Nov 20, 2025
Earnings per share (EPS)
0.58
Gross Margin
31.60%
Net Profit Margin
2.89%
Debt/Equity Ratio
32.3%

Ion Beam Applications SA Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Undervalued with adequate balance sheet.

1 Risk
4 Rewards

About IBAB

Founded
1986
Employees
2100
CEO
Olivier Legrain
WebsiteView website
www.iba-worldwide.com

Ion Beam Applications SA designs, produces, and markets solutions for cancer diagnosis and treatments in Belgium, the United States, and internationally. It operates through Proton Therapy and Other Accelerators; and Dosimetry segments. The Proton Therapy and Other Accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems. This segment also offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production of positron emission tomography or SPECT radioisotopes, as well as a line of industrial accelerators for sterilization and ionization. The Dosimetry segment provides solutions and services that enhances efficiency and minimizes errors in radiation therapy and medical imaging quality assurance and calibration procedures. The company has strategic research and development partnership with SCK CEN, a Belgian nuclear research center focusing on the development of Actinium-225, a radioactive isotope for the treatment of cancer. It also develops ConformalFLASH, a novel technique using the proton Bragg peak. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.

Market Insight

Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading

Belgian Market Performance

  • 7 Days: 2.5%
  • 3 Months: 7.0%
  • 1 Year: 7.3%
  • Year to Date: 12.8%
The market has climbed 2.5% in the last 7 days, lead by the Healthcare sector with a gain of 12%. In the last year, the market has climbed 7.3%. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›